In a 117-patient cohort, 35% waited over 60 days for neoadjuvant chemotherapy, most often because of added workup, second opinions or comorbidities.
|Videos|June 6, 2016
ASCO 2016: Mary McCabe on an Evaluation of Nurse-Led Survivorship Care
Author(s)Mary S. McCabe, RN, MA
Mary S. McCabe, RN, MA, discusses an evaluation of nurse practitioner-led survivorship care.
Advertisement
Mary S. McCabe, RN, MA, director, Survivorship Center, Memorial Sloan Kettering Cancer Center, discusses an evaluation of nurse practitioner-led survivorship care.
This analysis, presented at the 2016 ASCO Annual Meeting, looked at a model of care for patients with adult-onset cancers. The goal of the study was to show that at the appropriate time, post-treatment care could be transitioned to a nurse practitioner or a nurse practitioner group with expertise in survivorship care.
McCabe says it is crucial that comprehensive care is delivered and that it is affordable.
Advertisement
Related to this article
Interviews with 15 young women with breast cancer show fertility preservation decisions unfold under time pressure and carry into survivorship.
Lisa Carter-Bawa, PhD, MPH, APRN, explains how nurses can counter lung cancer fatalism by pairing honesty with hope and using teach-back.
Interim AYA-NAV data show most navigation components reached young patients with cancer as designed, though full sessions lagged during treatment.
As bispecifics and cell therapies move outpatient, Kate Kennedy, MSN, APRN, says nurses and APPs should focus on education and atypical infections.
A 3-minute video and quick-reference list of October's 7 FDA cancer approvals, with the biomarker and monitoring points nurses need for each.
Oral vitamin C did not slow clonal growth in the phase 2 EVITA trial but was linked to longer survival.
Kathryn Shady, PhD, RN, OCN, discusses research on emotional dissonance and vicarious trauma among hematology/oncology nurses.
Advertisement
Advertisement
Trending on Oncology Nursing News
1
Care Coordination Faces Neoadjuvant Chemotherapy Delays in MIBC
2
Outpatient Tarlatamab Feasible in Community Oncology, Real-World Data Show
3
Teaching Communication as a Clinical Skill for Breast Cancer Care
4
FDA Approves Amivantamab for Recurrent or Metastatic HNSCC
5